EUVIMEDEUVIMED entdecken
ÜbersichtsarbeitOpen Access · CC BY 4.0

Fundamentals of Rhenium-188 Radiopharmaceutical Chemistry

Janke Kleynhans iD, Adriano Duatti iD, Cristina Bolzati iD

Molecules · 2023

DOI: 10.3390/molecules28031487 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift Molecules, 2023. Verfasst von Janke Kleynhans und 2 weiteren Autor:innen. Beteiligte Einrichtung: Radiopharmaceutical Research, Department of Pharmaceutical and Pharmacological Sciences, Katholieke Universiteit Leuven, 3000 Leuven, Belgium. Hauptthemen laut MEDLINE: Radiopharmaceuticals, Rhenium. Die Arbeit wurde bisher 35-mal zitiert (Crossref) und nennt 73 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Italian Association for Cancer Research.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

The β− emitter, rhenium-188 (188Re), has long been recognized as an attractive candidate for targeted cancer radionuclide therapy (TRNT). This transition metal shares chemical similarities with its congener element technetium, whose nuclear isomer technetium-99m (99mTc) is the current workhorse of diagnostic nuclear medicine. The differences between these two elements have a significant impact on the radiolabelling methods and should always receive critical attention. This review aims to highlight what needs to be considered to design a successful radiopharmaceutical incorporating 118Re. Some of the most effective strategies for preparing therapeutic radiopharmaceuticals with 188Re are illustrated and rationalized using the concept of the inorganic functional group (core) and a simple ligand field theoretical model combined with a qualitative definition of frontiers orbitals. Of special interest are the Re(V) oxo and Re(V) nitrido functional groups. Suitable ligands for binding to these cores are discussed, successful clinical applications are summarized, and a prediction of viable future applications is presented. Rhenium-188 decays through the emission of a high energy beta particle (2.12 MeV max energy) and a half-life of 16.9 h. An ideal biological target would therefore be a high-capacity target site (transporters, potential gradients, tumour microenvironment) with less emphasis on saturable targets such as overexpressed receptors on smaller metastases.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

RadiopharmaceuticalsRheniumTechnetiumRadioisotopes

Stichwörter der Autor:innen

188W/188Re generatorfrontier orbitalsligand field theorynuclear medicineperrhenaterheniumtargeted radionuclide therapy (TRNT)theranostictransition metal chemistry

Substanzen

Rhenium-188RadiopharmaceuticalsTechnetiumRadioisotopesRhenium

Autor:innen und Institutionen

  • Radiopharmaceutical Research, Department of Pharmaceutical and Pharmacological Sciences, Katholieke Universiteit Leuven, 3000 Leuven, Belgium.
  • Department of Chemical and Pharmaceutical Sciences, University of Ferrara, 44121 Ferrara, Italy.
  • ICMATE-CNR, Corso Stati Uniti 4, 35127 Padua, Italy.

ORCID-Profile: Janke Kleynhans, Adriano Duatti, Cristina Bolzati

Förderung

  • Italian Association for Cancer Research

Zitieren

APA

Kleynhans, J., Duatti, A., & Bolzati, C. (2023). Fundamentals of Rhenium-188 Radiopharmaceutical Chemistry. Molecules. https://doi.org/10.3390/molecules28031487

Vancouver

Kleynhans J, Duatti A, Bolzati C. Fundamentals of Rhenium-188 Radiopharmaceutical Chemistry. Molecules. 2023. doi:10.3390/molecules28031487

BibTeX
@article{Kleynhans2023,
  author = {Kleynhans, Janke and Duatti, Adriano and Bolzati, Cristina},
  title = {Fundamentals of Rhenium-188 Radiopharmaceutical Chemistry},
  journal = {Molecules},
  year = {2023},
  doi = {10.3390/molecules28031487}
}
Kostenlos starten →